Drug Profile
Research programme: disulfide rich peptides - Protagonist Therapeutics
Alternative Names: Hepcidin agonists - Protagonist Therapeutics; Interleukin-23 receptor antagonist - Protagonist Therapeutics; Nav1.7 voltage gated sodium channel modulators - Protagonist ThearapeuticsLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator Protagonist Therapeutics
- Class Disulfides; Peptides
- Mechanism of Action Interleukin-23 receptor antagonists; Nav1.7 voltage-gated sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Neuropathic pain
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Inflammatory bowel diseases in USA (PO)
- 23 Mar 2023 Discontinued - Preclinical for Neuropathic pain in USA (Parenteral)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)